Drug Trial Radar · NCT07182838
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Oct 5, 2026
Primary completion
Jun 18, 2027
Study completion Oct 28, 2027
Sponsor
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairIndustry
- Sponsor type
- Industry
- Collaborators
- UnitedHealthcare
- First posted
- Sep 19, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 24 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients 1. Treat Infection of Multiple Gene Mutation HIV Virus Strains. 2. Activate Human Antigen Presentation Reaction to HIV Specific Antigen. 3. The human antigen presenting cells (APCs) can take up and process HIV target antigen protein into small peptide fragments, and then HIV virus can be killed by APCs directly.
Conditions
- HIV Infections
Interventions
HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous useBiological
* By the percutaneous route with the multiple puncture device * HIV GP160 0.1 mg x 1 mL plus BCG Organism 50 MG Mix
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of HIV (+) Participants:Time frame: Duration up to 4 weeks
- Rate of Positive HIV nucleic acid:Time frame: Duration up to 4 weeks
- Rate of Negative HIV nucleic acid:Time frame: Duration up to 4 weeks
- 20 HIV (+) Participants with IGRA blood test with HIV antigensTime frame: Duration up to 4 weeks
- 20 HIV (+) Participants with IGRA blood test with TB antigensTime frame: Duration up to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medicine Invention Design Incorporation - IORG0007849 - NPI 1023387701
Rockville, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.